BR112017028420A2 - vírus da enterite de pato e usos do mesmo - Google Patents

vírus da enterite de pato e usos do mesmo

Info

Publication number
BR112017028420A2
BR112017028420A2 BR112017028420-0A BR112017028420A BR112017028420A2 BR 112017028420 A2 BR112017028420 A2 BR 112017028420A2 BR 112017028420 A BR112017028420 A BR 112017028420A BR 112017028420 A2 BR112017028420 A2 BR 112017028420A2
Authority
BR
Brazil
Prior art keywords
enteritis virus
duck enteritis
duck
virus
dev
Prior art date
Application number
BR112017028420-0A
Other languages
English (en)
Inventor
Yukari Saeki
Saitoh Shuji
Original Assignee
Ceva Sante Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale filed Critical Ceva Sante Animale
Publication of BR112017028420A2 publication Critical patent/BR112017028420A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation
    • C12N2710/16362—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere ao dev e usos dos mesmos. a invenção é particularmente adequada para vacinar aves contra patógenos aviários.
BR112017028420-0A 2015-06-30 2016-06-29 vírus da enterite de pato e usos do mesmo BR112017028420A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15174515 2015-06-30
EPEP15174515.5 2015-06-30
PCT/EP2016/065132 WO2017001469A1 (en) 2015-06-30 2016-06-29 Duck enteritis virus and the uses thereof

Publications (1)

Publication Number Publication Date
BR112017028420A2 true BR112017028420A2 (pt) 2018-08-28

Family

ID=53496539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028420-0A BR112017028420A2 (pt) 2015-06-30 2016-06-29 vírus da enterite de pato e usos do mesmo

Country Status (11)

Country Link
US (5) US10202582B2 (pt)
EP (1) EP3317406A1 (pt)
JP (1) JP6802813B2 (pt)
CN (1) CN108368488B (pt)
BR (1) BR112017028420A2 (pt)
CA (1) CA2992158C (pt)
MX (1) MX2018000091A (pt)
PE (1) PE20180463A1 (pt)
RU (1) RU2721575C2 (pt)
UA (1) UA122339C2 (pt)
WO (1) WO2017001469A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6802813B2 (ja) * 2015-06-30 2020-12-23 セヴァ・サンテ・アニマールＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ アヒル腸炎ウイルス及びその使用
EP3263129A1 (en) * 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof
CN110904058B (zh) * 2018-09-14 2023-03-07 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 重组鸭瘟病毒疫苗及其构建方法和应用
CN113249340B (zh) * 2020-08-19 2022-07-19 浙江省农业科学院 一株双色荧光蛋白标记鸭瘟病毒及其构建方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
WO2002092826A2 (en) * 2001-05-09 2002-11-21 M's Science Corporation Composition and method for treating cancer using herpes virus
FR2916759B1 (fr) * 2007-05-29 2009-07-10 Adisseo France Sas Soc Par Act Peptide rumc presentant une activite antimicrobienne
CN102277368B (zh) * 2010-06-13 2013-12-25 中国农业科学院哈尔滨兽医研究所 鸭病毒性肠炎病毒感染性重组克隆系统及构建方法和应用
CN102533674B (zh) * 2010-12-08 2014-05-14 中国农业科学院哈尔滨兽医研究所 表达禽流感病毒血凝素基因的重组鸭病毒性肠炎病毒疫苗株及其构建方法和应用
CN103667351B (zh) * 2012-09-10 2017-01-25 中国农业科学院哈尔滨兽医研究所 以鸭病毒性肠炎病毒疫苗株为载体的重组病毒疫苗在鸡形目禽类中的应用
WO2014036735A1 (zh) 2012-09-10 2014-03-13 中国农业科学院哈尔滨兽医研究所 鸭病毒性肠炎病毒疫苗株作为表达载体在制备预防鸡形目禽类疾病的重组病毒疫苗中的应用
JP6802813B2 (ja) * 2015-06-30 2020-12-23 セヴァ・サンテ・アニマールＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ アヒル腸炎ウイルス及びその使用
EP3263129A1 (en) 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof

Also Published As

Publication number Publication date
US10711255B2 (en) 2020-07-14
CA2992158A1 (en) 2017-01-05
RU2721575C2 (ru) 2020-05-20
US10717967B2 (en) 2020-07-21
US20190144836A1 (en) 2019-05-16
UA122339C2 (uk) 2020-10-26
US20190136208A1 (en) 2019-05-09
US10711254B2 (en) 2020-07-14
RU2018103145A3 (pt) 2019-11-20
PE20180463A1 (es) 2018-03-06
CN108368488B (zh) 2022-04-05
JP2018519826A (ja) 2018-07-26
WO2017001469A1 (en) 2017-01-05
US20180187164A1 (en) 2018-07-05
US10202582B2 (en) 2019-02-12
JP6802813B2 (ja) 2020-12-23
US10704028B2 (en) 2020-07-07
MX2018000091A (es) 2018-02-19
CA2992158C (en) 2023-11-21
EP3317406A1 (en) 2018-05-09
CN108368488A (zh) 2018-08-03
US20190136209A1 (en) 2019-05-09
RU2018103145A (ru) 2019-07-30
US20190144835A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
CL2017000064A1 (es) Vacunas contra virus influenza y usos de las mismas
MA46766A (fr) Vaccin antigrippal
BR112018077210A2 (pt) vírus de enterite de pato e usos do mesmo
CL2017000063A1 (es) Vacunas contra virus influenza y usos de las mismas
HK1254668A1 (zh) 流感病毒複製抑制劑及其使用方法和用途
CL2016002413A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
BR112016016289A2 (pt) heteroaris e usos dos mesmos
BR112016027136A2 (pt) Válvula protética para tratamento de doenças que causam refluxo afetando os membros inferiores
BR112017026559A2 (pt) ceratoprótese e usos dos mesmos.
HK1245776A1 (zh) 流感病毒複製抑制劑及其使用方法和用途
DK3350162T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
ES2973289T3 (es) Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
BR112017028420A2 (pt) vírus da enterite de pato e usos do mesmo
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
HK1252416A1 (zh) 流感病毒複製抑制劑及其用途
BR112017003891A2 (pt) métodos e composições para induzir imunidade protetora contra infecção por filovírus
HK1244506A1 (zh) 用於流感病毒的減弱活疫苗
BR112017000895A2 (pt) componente de mancal, mancal, uso de um componente de mancal, e uso de um mancal
EP3305328A4 (en) Non-gelatin vaccine protectant composition and live attenuated influenza vaccine
MA42422A (fr) Inhibiteurs de la réplication des virus de la grippe
BR112016026470A2 (pt) Composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
EP3236997A4 (en) Dengue virus vaccine compositions and methods of use thereof
EP3091990A4 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
EP3484511A4 (en) VACCINE COMPOSITIONS FOR TREATING ZIKA VIRUS
BR112017016181A2 (pt) mdv1 recombinante e usos do mesmo

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]